Soya Isoflavone
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound | Soya isoflavones — genistein, daidzein and glycitein with their conjugates |
|---|---|
| Chemical class | Isoflavone aglycones and their 7-O-β-glucosides, malonyl and acetyl esters |
| Botanical source | Glycine max — germ (hypocotyl) or cotyledon, which differ |
| CAS | 446-72-0 (genistein) · 486-66-8 (daidzein) · 40957-83-3 (glycitein) |
| Declaration basis | Aglycone and glycoside figures differ by roughly 1.6× — state which |
| Metabolic variable | Equol production from daidzein occurs in only a minority of Western subjects |
| Claim strength | High for the declaration and equol issues; Emerging for menopausal endpoints |
| Buy from Herbuno | Soya Isoflavone Extract 40% Powder · Soy Isoflavones 80% (Glycine max) · Soy Isoflavones 40% (Glycine max) |
| Origin | Processed / Sourced from India |
| MOQ | R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above |
| Lead Time | Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days |
| Documentation | CoA & MSDS standard with every lot; phytosanitary on request |
Name origin: Isoflavones are flavonoids with the B-ring attached at the 3-position rather than the 2, and that structural shift gives them a spatial resemblance to oestradiol — which is why they are described as phytoestrogens. Genistein takes its name from Genista, dyer's broom, from which it was first isolated in 1899; daidzein from daidzu, the Japanese for soybean.
Traditional use and the epidemiological origin: Soy has been a dietary staple across East Asia for millennia, consumed principally as fermented and minimally processed foods — miso, natto, tempeh, tofu. Commercial interest in isoflavones arose from observational comparisons showing lower rates of menopausal vasomotor symptoms, and of hormone-related cancers, in East Asian than in Western populations, with dietary isoflavone intake proposed as a contributor. That hypothesis drove three decades of supplementation research.
Research trajectory: Supplementation trials have been persistently inconsistent, and the leading explanation is interpersonal metabolic variation. Daidzein is converted by particular gut bacteria to equol, a metabolite with considerably higher oestrogen receptor affinity, and only a minority of Western subjects carry the microbiota to do it — commonly estimated at around a quarter to a third, with higher proportions reported in Asian populations consuming traditional soy diets. A trial that does not stratify by equol producer status is averaging two different pharmacologies.
Commercial source: Soy isoflavone extracts are produced from soy germ (hypocotyl) or from defatted cotyledon meal by aqueous-alcoholic extraction and resin purification. The two source materials are not equivalent: germ is far richer in total isoflavones and relatively daidzein-rich, while cotyledon is relatively genistein-rich. Red clover and kudzu isoflavone extracts are different compounds entirely.
Evidence for Soya Isoflavone Applications
The aglycone-versus-glycoside declaration gap is the first thing to settle, and it is roughly 1.6-fold. In the bean, isoflavones exist predominantly as 7-O-beta-glucosides — genistin, daidzin, glycitin — and as their malonyl and acetyl esters, not as free aglycones. Removing the glucose moiety loses around 38% of the mass, so a "40% isoflavones" declaration means quite different things expressed as glycosides or as aglycone equivalents. State the basis explicitly: an 80% glycoside material and a 50% aglycone material can be the same thing. Claim strength: High.
Germ and cotyledon give different ratios, which matters because the three isoflavones are not interchangeable. Soy germ or hypocotyl carries far higher total isoflavone content and is relatively rich in daidzein and glycitein; defatted cotyledon meal is relatively genistein-rich. Because daidzein is the equol precursor and genistein has the higher intrinsic oestrogen receptor affinity of the two, the source material shifts the pharmacology as well as the assay. Specify the plant part and require the individual isoflavone profile, not just the total. Claim strength: High.
Equol producer status is the most plausible explanation for the inconsistent trial record. Specific gut bacteria convert daidzein to equol, which has substantially greater oestrogen receptor binding affinity than its precursor, and the capacity is present in only a minority of Western subjects — commonly estimated at a quarter to a third — with higher proportions in populations consuming traditional soy diets. Trials that do not stratify by producer status pool two pharmacologies, which would tend to dilute any real effect toward the null. Claim strength: Moderate.
Menopausal vasomotor evidence is modest and the European regulatory position is unfavourable. Meta-analyses of isoflavone supplementation for hot flush frequency and severity have reported small reductions with substantial heterogeneity between trials, and EFSA has not accepted health claims for isoflavones on menopausal symptoms, bone or skin. Effects where reported are considerably smaller than hormone therapy. This is a category where the commercial positioning runs well ahead of the regulatory and evidential position in most markets. Claim strength: Emerging.
The receptor pharmacology is genuinely interesting and is often misstated in both directions. Isoflavones bind both oestrogen receptor subtypes with preference for ER-beta over ER-alpha, and behave as selective modulators rather than as straightforward agonists, with tissue-dependent agonist and antagonist activity. Observational data from Asian cohorts with lifelong high soy intake have generally been reassuring and in some analyses protective with respect to breast cancer. That is not the same as establishing safety for concentrated supplemental isoflavones in oestrogen-sensitive conditions, where the honest position remains caution and clinical advice. Claim strength: Moderate for the pharmacology; Emerging for the clinical position.
Red clover and kudzu isoflavones are different compounds and should never be substituted on price or availability. Red clover, Trifolium pratense, yields principally biochanin A and formononetin, which are 4'-methylated precursors demethylated in vivo to genistein and daidzein respectively — so the pharmacology overlaps but the conversion step and the assay do not. Kudzu, Pueraria lobata, yields puerarin, a C-glycoside with its own profile. Keyword matching "isoflavone" across a catalogue produces exactly this error. Claim strength: High.
Sourcing soya isoflavone from Herbuno. We supply soy isoflavone extracts at 40% and 80% from Glycine max. Red clover and kudzu isoflavones are separate articles and are not substitutes.
State three things on the specification. The declaration basis — glycoside or aglycone equivalent, which differ by about 1.6×, so an 80% glycoside and a 50% aglycone material can be the same thing. The plant part, germ or cotyledon, since germ is daidzein-rich and cotyledon genistein-rich. And the individual isoflavone profile by HPLC rather than a total. Non-GMO documentation is available on request. All lots ship with CoA and MSDS; request a quotation for pilot or bulk volumes.
Dosage & Formulator Specification
Dose on aglycone equivalents and say so. Trials in the menopausal literature have commonly used 40 to 80 milligrams of total isoflavones daily expressed as aglycones, which at a 40% glycoside material means roughly 160 to 320 milligrams of extract once the 1.6-fold conversion is applied, or about 80 to 160 milligrams of an 80% glycoside material. Declaring extract weight or glycoside percentage without the aglycone equivalent leaves a formulator unable to match a published protocol, and that is the commonest error in this category.
The analytical specification should require the individual isoflavones, not a total. Request genistein, daidzein and glycitein each quantified by HPLC, with the basis stated, and the malonyl and acetyl conjugate content where relevant, since those are the predominant native forms and degrade on processing. A total-isoflavone figure conceals the germ-versus-cotyledon ratio difference, which shifts both the equol precursor loading and the receptor affinity profile of the material.
Handling is straightforward with one colour caveat. Soy isoflavone extracts are free-flowing pale cream to tan powders, poorly soluble in water as the aglycones and somewhat better as the glycosides, stable to heat and across a moderate pH range, and not notably hygroscopic. They will contribute colour and a characteristic beany or slightly bitter note to a pale or neutral matrix, which at the inclusion rates needed for a meaningful aglycone dose is usually noticeable and needs addressing at formulation.
Co-formulation and positioning require care in a regulated category. Isoflavones are commonly paired with calcium and vitamin D for bone positioning, or with black cohosh and other botanicals for menopausal products, and in both cases the combination is conventional rather than tested as a combination. The regulatory position on isoflavone claims is restrictive in the European Union and varies elsewhere, so resolve the permitted claim set per market before artwork, and note that concentrated supplemental isoflavones in oestrogen-sensitive conditions is a clinical-advice matter rather than a label warning.
Standard botanical coverage applies: heavy metals, pesticide residues, microbiological limits, residual solvents with the extraction system named, loss on drying, ash, and the species confirmed by binomial with the plant part stated. Soy is a major declarable allergen in most markets, so the allergen statement is mandatory rather than optional even for a purified extract. Non-GMO documentation should be requested explicitly, since commodity soy is predominantly genetically modified and the identity-preserved supply chain is what carries that status.
One cross-catalogue discipline point. Three distinct isoflavone materials are routinely conflated: soy from Glycine max yields genistein, daidzein and glycitein; red clover from Trifolium pratense yields biochanin A and formononetin, which are 4'-methylated precursors requiring in vivo demethylation to genistein and daidzein; and kudzu from Pueraria lobata yields puerarin, a C-glycoside with a different profile again. They are not substitutes, their assays are not comparable, and a trial using one does not support a claim on another. A purchase order saying "isoflavones 40%" without the species is not a specification.
Frequently Asked Questions — Soya Isoflavone
What does "40% isoflavones" actually mean?
Depends on the basis, and the gap is about 1.6-fold. In the bean, isoflavones are predominantly 7-O-beta-glucosides plus malonyl and acetyl esters, not free aglycones, and removing the glucose loses around 38% of the mass. An 80% glycoside material and a 50% aglycone material can be the same thing. State which.
Does it matter whether it comes from germ or cotyledon?
Yes, and the assay conceals it. Soy germ carries far higher total isoflavones and is relatively daidzein- and glycitein-rich; defatted cotyledon is relatively genistein-rich. Since daidzein is the equol precursor and genistein has higher intrinsic receptor affinity, the source shifts the pharmacology as well as the number. Specify the part and the individual profile.
Why are the trials so inconsistent?
Equol producer status is the leading explanation. Specific gut bacteria convert daidzein to equol, which has substantially greater oestrogen receptor affinity, and only a minority of Western subjects — commonly a quarter to a third — carry the capacity. Trials that do not stratify are pooling two pharmacologies, which dilutes any real effect toward the null.
Can I make a menopause claim?
Not in the EU. Meta-analyses report small reductions in hot flush frequency and severity with substantial heterogeneity, and EFSA has not accepted isoflavone claims on menopausal symptoms, bone or skin. Effects where reported are much smaller than hormone therapy. Resolve the permitted claim set per market before artwork.
Can red clover isoflavones substitute for soy?
No. Red clover yields biochanin A and formononetin, which are 4'-methylated precursors requiring in vivo demethylation to genistein and daidzein — overlapping pharmacology, different conversion step, non-comparable assay. Kudzu yields puerarin, a C-glycoside, different again. A trial on one does not support a claim on another.
What documentation should I require?
Individual isoflavones by HPLC with the basis stated, the plant part, and the species by binomial. Soy is a major declarable allergen in most markets, so the allergen statement is mandatory even for a purified extract. Request non-GMO documentation explicitly — commodity soy is predominantly genetically modified and only an identity-preserved chain carries that status.